A partir de cette page vous pouvez :
Retourner au premier écran avec les dernières notices... |
Descripteurs (mots clés)
Thésaurus Mesh
> S > Syndromes de l'oeil sec > Syndromes de l'oeil sec / diétothérapie
Syndromes de l'oeil sec / diétothérapie
Ajouter le résultat dans votre panier Affiner la recherche
Etendre la recherche sur niveau(x) vers le bas
Effect of a Novel Omega-3 and Omega-6 Fatty Acid Supplement on Dry Eye Disease: A 3-month Randomized Controlled Trial / Alison Ng in OVS : Optometry & Vision Science, vol. 99, 01 (Janvier 2022)
[article]
in OVS : Optometry & Vision Science > vol. 99, 01 (Janvier 2022)
Titre : Effect of a Novel Omega-3 and Omega-6 Fatty Acid Supplement on Dry Eye Disease: A 3-month Randomized Controlled Trial Type de document : article de périodique Auteurs : Alison Ng ; Jill Woods ; Theresa Jahn ; Lyndon Jones ; Jenna Sullivan Ritter, Année de publication : 2022 Langues : Français (fre) Descripteurs (mots clés) : [Thésaurus Mesh]:S:Syndromes de l'oeil sec:Syndromes de l'oeil sec / diétothérapie
[Thésaurus Mesh]:S:Syndromes de l'oeil sec:Syndromes de l'oeil sec / thérapie
[Thésaurus Mesh]Acides gras omega-3
[Thésaurus Mesh]Collecte de données
[Thésaurus Mesh]Syndromes de l'oeil secRésumé : SIGNIFICANCE
Supplementing diet with a novel combination of omega-3 and omega-6 fatty acids significantly improved symptoms in extremely symptomatic participants with dry eye disease (DED).
PURPOSE
This study aimed to determine the effect of daily intake of a novel combination of essential fatty acids on signs and symptoms of DED.
METHODS
Participants with moderate to severe DED were enrolled in a prospective, randomized, double-masked parallel group study. Participants ingested either the treatment supplement containing omega-3 and omega-6 fatty acids (1200 mg eicosapentaenoic acid, 300 mg docosahexaenoic acid, 150 mg γ-linoleic acid) or the placebo (coconut and olive oil) daily for 3 months. To determine compliance, Omega-3 Index blood tests were conducted. At baseline and at 1 and 3 months, the following assessments were conducted: Ocular Surface Disease Index (OSDI) questionnaire and Symptom Assessment Questionnaire in Dry Eye, noninvasive tear breakup time, tear meniscus height, tear osmolarity, ocular redness, surface staining, Schirmer test, and meibography.
RESULTS
Fifty participants (mean ± standard deviation baseline OSDI score, 52.2 ± 16.5) completed the study: 24 randomized to treatment and 26 randomized to placebo. Although there was an improvement in OSDI score at 3 months for both groups (treatment: −13.4 points, P = .003; placebo: −7.8 points, P = .02), participants with baseline OSDI scores >52 demonstrated an even larger significant improvement in symptoms with the treatment at 3 months compared with baseline (n = 13, −20.8 points, P = .002). There were no significant changes in any of the ocular assessments at 1 or 3 months (all P > .05). After 3 months, Omega-3 Index increased by 34% in the treatment group (baseline, 5.3 ± 0.8; 3 months, 8.0 ± 2.1; P < .001) and did not change in the placebo group (baseline, 4.8 ± 0.8; 3 months, 4.8 ± 0.6; P = .95).
CONCLUSIONS
Supplementation with eicosapentaenoic acid, docosahexaenoic acid, and γ-linoleic acid resulted in a significant and clinically meaningful improvement of dry eye symptoms in extremely symptomatic participants with DED (OSDI ≥52).Permalink : https://bibliotheque.helb-prigogine.be/opac_css/index.php?lvl=notice_display&id= [article]Exemplaires
Cote Support Localisation Section Disponibilité aucun exemplaire